CCG
ALXN

Cypress Capital Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Cypress Capital Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,102
Closed -$485K – 294
2020
Q4 		$485K Buy
3,102
+1,020
+49% +$131K 0.07% 200
2020
Q3 		$238K Buy
2,082
+47
+2% +$5.07K 0.04% 233
2020
Q2 		$228K Buy
+2,035
New +$216K 0.04% 227
2016
Q1 		– Sell
-2,333
Closed -$445K – 186
2015
Q4 		$445K Hold
2,333
– – 0.11% 133
2015
Q3 		$365K Hold
2,333
– – 0.09% 151
2015
Q2 		$422K Sell
2,333
-407
-15% -$70.2K 0.1% 145
2015
Q1 		$475K Buy
2,740
+407
+17% +$73.7K 0.11% 145
2014
Q4 		$432K Hold
2,333
– – 0.1% 148
2014
Q3 		$387K Hold
2,333
– – 0.09% 145
2014
Q2 		$365K Hold
2,333
– – 0.09% 156
2014
Q1 		$355K Hold
2,333
– – 0.09% 155
2013
Q4 		$310K Hold
2,333
– – 0.08% 155
2013
Q3 		$271K Hold
2,333
– – 0.07% 162
2013
Q2 		$215K Buy
+2,333
New +$225K 0.04% 204

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cypress Capital Group's ALXN Position: Q1 2021 in Review

Cypress Capital Group sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 3,102 shares — an estimated $485K sold.

Cypress Capital Group first reported a position in ALXN in Q2 2013 and held it in 14 quarters. The position peaked at $485K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Cypress Capital Group reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Cypress Capital Group sold 3,102 Alexion Pharmaceuticals shares in Q1 2021, an estimated $485K.
  • Cypress Capital Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Cypress Capital Group's Alexion Pharmaceuticals position peaked at $485K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Cypress Capital Group's 13F filing for Q1 2021, filed 14 Apr 2021.